where IBA wishes to market a product or device. IBA is authorized to market its particle therapy 
devices in the United States (FDA), the 
European Union (LRQA), Australia (TGA), Russia (Gost-R), South Korea (MFDS) and 
Taiwan (TFDA), Singapore (SFDA), and Japan 
(Shonin). Authorizations 
may 
always 
be 
revoked. Moreover, as IBAs equipment evolves 
technologically, further authorizations may be 
required.